Citadel Advisors’s Genocea Biosciences, Inc. GNCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-1,843,112
| Closed | -$2.3M | – | 14913 |
|
|
2022
Q1 | $2.3M | Buy |
1,843,112
+47,617
| +3% | +$51.9K | ﹤0.01% | 5784 |
|
|
2021
Q4 | $2.08M | Sell |
1,795,495
-58,331
| -3% | -$86.9K | ﹤0.01% | 6138 |
|
|
2021
Q3 | $3.56M | Sell |
1,853,826
-18,410
| -1% | -$36.2K | ﹤0.01% | 4989 |
|
|
2021
Q2 | $4.38M | Buy |
1,872,236
+41,450
| +2% | +$99.9K | ﹤0.01% | 4723 |
|
|
2021
Q1 | $4.96M | Buy |
1,830,786
+22,054
| +1% | +$65.3K | ﹤0.01% | 4278 |
|
|
2020
Q4 | $4.38M | Buy |
1,808,732
+10,729
| +0.6% | +$24.4K | ﹤0.01% | 3902 |
|
|
2020
Q3 | $4.12M | Buy |
1,798,003
+1,758,244
| +4,422% | +$4.61M | ﹤0.01% | 3442 |
|
|
2020
Q2 | $92K | Buy |
39,759
+18,846
| +90% | +$43.4K | ﹤0.01% | 9040 |
|
|
2020
Q1 | $36K | Sell |
20,913
-29,442
| -58% | -$59.5K | ﹤0.01% | 9149 |
|
|
2019
Q4 | $104K | Buy |
50,355
+35,882
| +248% | +$85.1K | ﹤0.01% | 8533 |
|
|
2019
Q3 | $42K | Sell |
14,473
-2,817
| -16% | -$9.62K | ﹤0.01% | 8756 |
|
|
2019
Q2 | $68K | Buy |
+17,290
| New | +$90.2K | ﹤0.01% | 8649 |
|
|
2019
Q1 | – | Sell |
-4,989
| Closed | -$11K | – | 10239 |
|
|
2018
Q4 | $11K | Buy |
+4,989
| New | +$24.8K | ﹤0.01% | 8921 |
|
|
2017
Q4 | – | Sell |
-2,778
| Closed | -$27.9K | – | 8706 |
|
|
2017
Q3 | $32K | Buy |
2,778
+1,405
| +102% | +$53.3K | ﹤0.01% | 7274 |
|
|
2017
Q2 | $57K | Buy |
+1,373
| New | +$66.1K | ﹤0.01% | 7066 |
|
Other funds holding GNCA
Citadel Advisors's GNCA Position: Q2 2022 in Review
Citadel Advisors sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 1,843,112 shares — an estimated $2.3M sold.
Citadel Advisors first reported a position in GNCA in Q2 2017 and held it in 15 quarters. The position peaked at $4.96M in Q1 2021. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.
- Citadel Advisors reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
- Citadel Advisors sold 1,843,112 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $2.3M.
- Citadel Advisors first reported a position in Genocea Biosciences, Inc. in Q2 2017 and held it in 15 quarters.
- Citadel Advisors's Genocea Biosciences, Inc. position peaked at $4.96M in Q1 2021.
- 5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.